How long did the patient take Pertuzumab?

When Pertuzumab (Pertuzumab) and trastuzumab (trastuzumab) are used to treat HER2+ early-stage breast cancer as adjuvant therapy (postoperative), the regimen can be continued every 3 weeks for one year (up to 18 cycles), but doctors will remind patients that treatment may need to be stopped early due to side effects or if the breast cancer recurs. When used as neoadjuvant therapy (preoperatively), patients will receive pertuzumab, trastuzumab, and chemotherapy every 3 weeks for 3-6 cycles. If patients start pertuzumab and trastuzumab-based therapy before surgery, they may continue treatment after surgery until they have completed approximately 1 year (a total of 18 cycles).